Immunogen, inc. (IMGN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Revenues:
License and milestone fees

-

-

-

-

-

-

-

-

-

-

-

31,080

-

-

76

76

10,077

10,692

6,070

5,086

5,078

41,417

6,234

305

305

25,678

13,167

855

22,010

429

933

950

999

6,025

1,187

2,859

858

866

1,810

Royalty revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

195

-

-23

5,099

4,625

4,166

3,400

2,558

2,335

2,053

592

-

-

-

-

-

-

-

-

-

-

-

Non-cash royalty revenue related to the sale of future royalties

-

-

-

-

-

-

-

-

-

-

-

6,439

-

-

6,184

5,944

7,380

6,291

5,684

5,484

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development support

-

-

-

-

-

-

-

-

-

-

-

902

-

-

1,354

1,335

1,059

848

772

708

532

832

776

1,327

1,948

1,922

1,990

2,203

2,257

2,036

1,377

1,184

1,320

945

1,068

1,566

2,190

2,005

1,495

Clinical materials revenue

-

-

-

-

-

-

-

-

-

-

-

599

-

-

46

53

1,198

3

2,325

1,356

718

1,426

2,027

711

2,064

125

8

181

734

147

1,781

818

933

647

281

2,080

2,163

1,307

106

Total revenues

13,287

44,864

13,281

15,542

8,584

13,416

10,928

9,287

19,815

39,448

8,480

39,020

28,499

13,846

7,660

7,408

19,714

18,029

14,851

12,611

11,427

48,300

13,203

5,743

6,875

30,060

17,218

3,831

25,001

2,612

4,091

2,952

3,252

7,617

2,536

6,505

5,211

4,178

3,411

Operating expenses:
Research and development

27,408

26,055

21,015

28,559

38,893

43,681

47,243

38,701

44,831

39,843

31,689

35,319

32,888

33,657

32,909

38,652

36,094

38,199

35,132

30,437

25,666

27,647

28,018

25,787

38,280

20,862

22,029

20,399

21,318

21,656

23,700

19,539

16,933

15,559

17,161

18,261

15,763

16,004

13,425

General and administrative

8,864

9,803

9,208

8,700

10,778

9,752

8,347

8,652

9,995

9,048

7,908

8,836

8,119

8,536

9,459

9,298

11,235

8,054

8,329

7,261

7,000

6,872

7,095

6,456

6,040

5,447

6,526

5,373

4,995

5,464

5,639

5,726

5,021

4,834

4,841

4,438

4,550

3,688

3,364

Restructuring charge

825

512

1,020

19,342

559

406

870

686

1,731

393

0

0

386

301

4,130

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

37,097

36,370

31,243

56,601

50,230

53,839

56,460

48,039

56,557

49,284

39,597

44,155

41,393

42,494

46,498

47,950

47,329

46,253

43,461

37,698

32,666

34,519

35,113

32,243

44,320

26,309

28,555

25,772

26,313

27,120

29,339

25,265

21,954

20,393

22,002

22,699

20,313

19,692

16,789

Loss from operations

-23,810

8,494

-17,962

-41,059

-41,646

-40,423

-45,532

-38,752

-36,742

-9,836

-31,117

-5,135

-12,894

-28,648

-38,838

-40,542

-27,615

-28,224

-28,610

-25,087

-21,239

13,781

-21,910

-26,500

-37,445

3,751

-11,337

-21,941

-1,312

-24,508

-25,248

-22,313

-18,702

-12,776

-19,466

-16,194

-15,102

-15,514

-13,378

Investment income, net

646

683

1,032

1,287

1,422

-

-

-

-

-

-

143

-

113

146

106

108

60

51

33

14

14

8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes

5,702

5,354

4,275

3,818

3,432

2,428

2,546

2,611

3,046

3,221

3,385

3,501

3,575

3,647

5,018

4,956

4,972

5,059

5,143

5,437

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense on convertible senior notes

24

24

24

23

24

25

23

23

24

28

762

1,125

1,125

1,099

1,150

138

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash debt conversion expense

-

-

-

-

-

-

-

-

-

724

22,191

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense, net

-198

1,015

-521

167

-71

-

-

-

-

-

-

751

-

-871

129

-392

551

-4

-38

17

-393

-160

-380

-43

-7

62

111

-60

-39

115

56

-167

33

23

-17

44

99

1,281

490

Net loss

-29,088

4,814

-21,750

-43,446

-43,751

-41,799

-46,807

-41,624

-38,613

-13,118

-56,682

-8,867

-17,345

-34,152

-44,731

-45,922

-31,928

-33,227

-33,740

-30,474

-21,618

13,635

-22,282

-26,499

-37,452

3,813

-11,226

-21,875

-1,351

-24,393

-25,192

-22,414

-18,669

-12,753

-19,483

-16,150

-15,003

-14,233

-12,888

Loss before benefit for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22,414

-

-

-

-16,150

-15,003

-14,233

-12,888

Basic and diluted net loss per common share (in dollar per share)

-0.17

0.03

-0.15

-0.29

-0.30

-0.28

-0.32

-0.31

-0.30

-0.11

-0.61

-0.10

-0.20

-0.39

-0.51

-0.53

-0.37

-0.38

-0.39

-0.35

-0.25

0.16

-0.26

-0.31

-0.44

0.04

-0.13

-0.26

-0.02

-0.29

-0.30

-0.29

-0.24

-0.17

-0.26

-0.23

-0.22

-0.21

-0.19

Basic and diluted weighted average common shares outstanding (in shares)

166,947

148,823

148,479

148,129

147,813

-

-

-

-

-

-

87,174

-

87,214

86,990

87,062

87,035

-

86,838

-

-

-

85,872

-

85,684

-

85,010

-

84,279

-

83,350

77,408

76,961

76,523

76,364

-

-

-

-

Basic weighted average common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86,080

85,935

-

-

-

85,431

-

-

-

84,147

-

-

-

-

-

-

-

-

-

Dilutive impact of potential common shares (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

730

-

-

-

1,845

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted weighted average common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86,665

-

-

-

87,276

-

-

-

84,147

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-29,088

4,814

-21,750

-43,446

-43,751

-

-

-

-

-

-

-8,867

-

-34,152

-44,731

-45,922

-31,928

-

-33,740

-30,474

-21,618

13,635

-22,282

-26,499

-37,452

3,813

-11,226

-21,875

-1,351

-24,393

-25,192

-22,414

-18,669

-12,753

-19,483

-

-

-

-

License and milestone fees
Total revenues

283

29,551

79

5,079

79

1,747

672

1,321

11,540

29,580

79

-

18,730

5,076

76

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash royalty revenue related to the sale of future royalties
Total revenues

12,997

15,313

13,202

10,412

8,488

9,281

8,441

7,242

7,190

7,587

6,503

-

7,613

6,710

6,184

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development support
Total revenues

7

0

0

51

17

218

388

388

383

452

650

-

1,478

1,427

1,354

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical materials revenue
Total revenues

-

-

-

-

-

2,170

1,427

336

702

1,829

1,248

-

678

633

46

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-